Mannkind reported $17.46M in Cost of Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Adma Biologics ADMA:US USD 31.43M 5.3M
Biocryst Pharmaceuticals BCRX:US USD 3.61M 3.37M
Dynavax Technologies DVAX:US USD 61.33M 22.04M
Eli Lilly And LLY:US USD 1.55B 31M
Halozyme Therapeutics HALO:US USD 47.32M 13.38M
Insmed INSM:US USD 13.47M 2.92M
Karyopharm Therapeutics KPTI:US USD 980K 41K
MacroGenics MGNX:US USD 3.14M 741K
Mannkind MNKD:US USD 17.46M 4.54M
Merk MRK:US USD 3.36B 519M
Novavax NVAX:US USD 434.59M 163.52M
Novo Nordisk A Fs NVO:US DKK 8.26B 1.06B
Peregrine Pharmaceuticals PPHM:US USD 30.61M 3.03M
Pfizer PFE:US USD 9.82B 3.73B